Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Journal of Virological Methods
James LogueLisa E Hensley

Abstract

As part of the scientific community's development of medical countermeasures against Ebola virus disease, optimization of standardized assays for product evaluation is paramount. The recent outbreak heightened awareness to the scarcity of available assays and limited information on performance and reproducibility. To evaluate the immunogenicity of vaccines entering Phase I-III trials and to identify survivors, two enzyme-linked immunosorbent assays, the Filovirus Animal Non-Clinical Group assay and the Alpha Diagnostics International assay, were evaluated for detection of immunoglobulin G against Ebola virus glycoprotein. We found that the Filovirus Animal Nonclinical Group assay produced a wider range of relative antibody concentrations, higher assay precision, larger relative accuracy range, and lower regional background. Additionally, to sufficiently power a vaccine trial, use of the Filovirus Animal Nonclinical Group assay would require one third the number of participants than the Alpha Diagnostics International assay. This reduction in needed study participants will require less money, fewer man hours, and much less time to evaluate vaccine immunogenicity.

References

Jan 14, 1998·Nature Medicine·L XuG J Nabel
Oct 3, 2007·The AAPS Journal·John W A Findlay, Robert F Dillard
Oct 16, 2015·The New England Journal of Medicine·Suzanne E MateGustavo Palacios
Oct 16, 2015·The New England Journal of Medicine·Gibrilla F DeenFoday Sahr
Nov 13, 2015·Journal of the Royal Society, Interface·Wan YangJeffrey Shaman
Jan 16, 2016·Clinical Trials : Journal of the Society for Clinical Trials·Stephen B KennedyTolbert G Nyenswah
Jan 27, 2016·Emerging Infectious Diseases·Robert J FischerVincent J Munster
Mar 5, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·William A Fischer, David A Wohl
Apr 6, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy M UyekiUte Ströher
Oct 30, 2016·The Journal of Infectious Diseases·Mamadou S SowUNKNOWN Postebogui Study Group
Jul 8, 2016·Science Advances·David J BlackleyGustavo Palacios
Aug 9, 2016·The Journal of Hospital Infection·N E MacDermott, D G Bausch
Oct 12, 2017·The New England Journal of Medicine·Stephen B KennedyUNKNOWN PREVAIL I Study Group

❮ Previous
Next ❯

Citations

Aug 10, 2018·Statistics in Medicine·Dean Follmann
Jan 31, 2021·NPJ Vaccines·Helen R WagstaffeMartin R Goodier
Mar 7, 2021·Vaccines·Jayanthi WolfJakub K Simon

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assays
ELISA
ELISAs

Clinical Trials Mentioned

NCT02344407
NCT02431923

Software Mentioned

Softmax Pro
Gen5
BioTek
Softmax

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Emerging Infectious Diseases
Nadia WauquierEric M Leroy
Annals of African Medicine
Saurabh RamBihariLal ShrivastavaJegadeesh Ramasamy
The Lancet Infectious Diseases
Shuo SuJiyong Zhou
Medical Microbiology and Immunology
Verena KrählingEuropean Mobile Laboratory consortium
© 2022 Meta ULC. All rights reserved